Antimicrobial Effects of Varied Combinations of Meropenem, Sulbactam, and Colistin on a Multidrug-Resistant Acinetobacter baumannii Isolate That Caused Meningitis and Bacteremia

2008 ◽  
Vol 14 (3) ◽  
pp. 233-237 ◽  
Author(s):  
Chen-Hsiang Lee ◽  
Ya-Fen Tang ◽  
Lin-Hui Su ◽  
Chun-Chih Chien ◽  
Jien-Wei Liu
Keyword(s):  
Acinetobacter Baumannii ◽  
Multidrug Resistant ◽  
Antimicrobial Effects ◽  
Baumannii Isolate

scholarly journals Complete Genome Sequence of a Multidrug-Resistant Acinetobacter baumannii Isolate Obtained from a Mexican Hospital (Sequence Type 422)

2016 ◽  
Vol 4 (3) ◽  
Author(s):  
Semiramis Castro-Jaimes ◽  
Abraham David Salgado-Camargo ◽  
Lucía Graña-Miraglia ◽  
Luis Lozano ◽  
Paola Bocanegra-Ibarias ◽  
...  
Keyword(s):  
Intensive Care ◽  
Acinetobacter Baumannii ◽  
Genome Sequence ◽  
Complete Genome Sequence ◽  
Complete Genome ◽  
Hematologic Malignancies ◽  
Multidrug Resistant ◽  
Sequence Type ◽  
Nosocomial Pathogen ◽  
Baumannii Isolate

Acinetobacter baumannii has emerged as a dangerous nosocomial pathogen, particularly for severely ill patients in intensive care units and patients with hematologic malignancies. Here, we present the complete genome sequence of a multidrug-resistant A. baumannii isolate, recovered from a Mexican hospital and classified as sequence type 422 according to the multilocus sequence typing Pasteur scheme.

scholarly journals Real-Time Sequencing To Decipher the Molecular Mechanism of Resistance of a Clinical Pan-Drug-Resistant Acinetobacter baumannii Isolate from Marseille, France

2012 ◽  
Vol 57 (1) ◽  
pp. 592-596 ◽  
Author(s):  
Jean-Marc Rolain ◽  
Seydina M. Diene ◽  
Marie Kempf ◽  
Gregory Gimenez ◽  
Catherine Robert ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Molecular Mechanisms ◽  
Multidrug Resistant ◽  
Drug Resistant ◽  
Two Component System ◽  
Genome Sequences ◽  
Component System ◽  
Content Type ◽  
Two Component ◽  
Baumannii Isolate

ABSTRACTWe compare the whole-genome sequences of two multidrug-resistant clinicalAcinetobacter baumanniiisolates recovered in the same patient before (ABIsac_ColiS susceptible to colistin and rifampin only) and after (ABIsac_ColiR resistant to colistin and rifampin) treatment with colistin and rifampin. We decipher all the molecular mechanisms of antibiotic resistance, and we found mutations in therpoBgene and in the PmrAB two-component system explaining resistance to rifampin and colistin in ABIsac_ColiR, respectively.

scholarly journals First Genome Sequence of a Mexican Multidrug-Resistant Acinetobacter baumannii Isolate

2016 ◽  
Vol 4 (2) ◽  
Author(s):  
Lucía Graña-Miraglia ◽  
Luis Lozano ◽  
Semiramis Castro-Jaimes ◽  
Miguel A. Cevallos ◽  
Patricia Volkow ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Mexico City ◽  
Genome Sequence ◽  
Draft Genome ◽  
Tertiary Hospital ◽  
Multidrug Resistant ◽  
Genomic Diversity ◽  
Nosocomial Pathogen ◽  
Starting Point ◽  
Baumannii Isolate

Acinetobacter baumannii has emerged as an important nosocomial pathogen worldwide. Here, we present the draft genome of the first multidrug-resistant A. baumannii isolate, sampled from a tertiary hospital in Mexico City. This genome will provide a starting point for studying the genomic diversity of this species in Mexico.

scholarly journals Efficacy of Lysophosphatidylcholine as Direct Treatment in Combination with Colistin against Acinetobacter baumannii in Murine Severe Infections Models

Antibiotics ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 194
Author(s):  
Andrea Miró-Canturri ◽  
Rafael Ayerbe-Algaba ◽  
Manuel Enrique Jiménez-Mejías ◽  
Jerónimo Pachón ◽  
Younes Smani
Keyword(s):  
Acinetobacter Baumannii ◽  
Multidrug Resistant ◽  
Experimental Models ◽  
Antimicrobial Treatment ◽  
Clinical Settings ◽  
Monotherapy Group ◽  
Bacterial Concentration ◽  
Sepsis Model ◽  
Severe Infections ◽  
Stimulation Of

The stimulation of the immune response to prevent the progression of an infection may be an adjuvant to antimicrobial treatment. Here, we aimed to evaluate the efficacy of lysophosphatidylcholine (LPC) treatment in combination with colistin in murine experimental models of severe infections by Acinetobacter baumannii. We used the A. baumannii Ab9 strain, susceptible to colistin and most of the antibiotics used in clinical settings, and the A. baumannii Ab186 strain, susceptible to colistin but presenting a multidrug-resistant (MDR) pattern. The therapeutic efficacies of one and two LPC doses (25 mg/kg/d) and colistin (20 mg/kg/8 h), alone or in combination, were assessed against Ab9 and Ab186 in murine peritoneal sepsis and pneumonia models. One and two LPC doses combined with colistin and colistin monotherapy enhanced Ab9 and Ab186 clearance from spleen, lungs and blood and reduced mice mortality compared with those of the non-treated mice group in both experimental models. Moreover, one and two LPC doses reduced the bacterial concentration in tissues and blood in both models and increased mice survival in the peritoneal sepsis model for both strains compared with those of the colistin monotherapy group. LPC used as an adjuvant of colistin treatment may be helpful to reduce the severity and the resolution of the MDR A. baumannii infection.

scholarly journals Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 96
Author(s):  
Stephen J. Dollery ◽  
Daniel V. Zurawski ◽  
Elena K. Gaidamakova ◽  
Vera Y. Matrosova ◽  
John K. Tobin ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Treatment Options ◽  
Bacterial Pathogen ◽  
Multidrug Resistant ◽  
Bacterial Cells ◽  
Wound Infections ◽  
Protein Profiles ◽  
Vaccine Candidates ◽  
Rich Media ◽  
Life Threatening

Acinetobacter baumannii is a bacterial pathogen that is often multidrug-resistant (MDR) and causes a range of life-threatening illnesses, including pneumonia, septicemia, and wound infections. Some antibiotic treatments can reduce mortality if dosed early enough before an infection progresses, but there are few other treatment options when it comes to MDR-infection. Although several prophylactic strategies have been assessed, no vaccine candidates have advanced to clinical trials or have been approved. Herein, we rapidly produced protective whole-cell immunogens from planktonic and biofilm-like cultures of A. baumannii, strain AB5075 grown using a variety of methods. After selecting a panel of five cultures based on distinct protein profiles, replicative activity was extinguished by exposure to 10 kGy gamma radiation in the presence of a Deinococcus antioxidant complex composed of manganous (Mn2+) ions, a decapeptide, and orthophosphate. Mn2+ antioxidants prevent hydroxylation and carbonylation of irradiated proteins, but do not protect nucleic acids, yielding replication-deficient immunogenic A. baumannii vaccine candidates. Mice were immunized and boosted twice with 1.0 × 107 irradiated bacterial cells and then challenged intranasally with AB5075 using two mouse models. Planktonic cultures grown for 16 h in rich media and biofilm cultures grown in static cultures underneath minimal (M9) media stimulated immunity that led to 80–100% protection.

Sign in / Sign up

Export Citation Format

Share Document